83 related articles for article (PubMed ID: 10808199)
1. The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.
Golay H; Jurkovic Mlakar S; Mlakar V; Nava T; Ansari M
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31404983
[TBL] [Abstract][Full Text] [Related]
2. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Snowden JA; Saccardi R; Orchard K; Ljungman P; Duarte RF; Labopin M; McGrath E; Brook N; de Elvira CR; Gordon D; Poirel HA; Ayuk F; Beguin Y; Bonifazi F; Gratwohl A; Milpied N; Moore J; Passweg J; Rizzo JD; Spellman SR; Sierra J; Solano C; Sanchez-Guijo F; Worel N; Gusi A; Adams G; Balan T; Baldomero H; Macq G; Marry E; Mesnil F; Oldani E; Pearce R; Perry J; Raus N; Schanz U; Tran S; Wilcox L; Basak GW; Chabannon C; Corbacioglu S; Dolstra H; Kuball J; Mohty M; Lankester A; Montoto S; Nagler A; Styczynski J; Yakoub-Agha I; de Latour RP; Kroeger N; Brand R; de Wreede LC; van Zwet E; Putter H
Bone Marrow Transplant; 2020 Apr; 55(4):681-694. PubMed ID: 31636397
[TBL] [Abstract][Full Text] [Related]
3. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.
Snowden JA; Saccardi R; Allez M; Ardizzone S; Arnold R; Cervera R; Denton C; Hawkey C; Labopin M; Mancardi G; Martin R; Moore JJ; Passweg J; Peters C; Rabusin M; Rovira M; van Laar JM; Farge D; ;
Bone Marrow Transplant; 2012 Jun; 47(6):770-90. PubMed ID: 22002489
[TBL] [Abstract][Full Text] [Related]
4. Genome editing in clinical practice: A model study for next-gen hematopoietic cell transplants in hematologic malignancies.
Derigs P; Müller-Tidow C
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101210. PubMed ID: 38435129
[No Abstract] [Full Text] [Related]
5. Evolution of dosimetric treatment planning for pediatric total lymphoid irradiation (TLI): a single-institution experience.
Ferrer C; Huertas C; Ocanto A; García D; Plaza R; Mínguez C; de la Monja P; Escribano A; Pérez A; Sáez M
Rep Pract Oncol Radiother; 2023; 28(6):772-783. PubMed ID: 38515822
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft
Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X
Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing.
Wang A; Li W; Zhao F; Zheng Z; Yang T; Wang S; Yan J; Lan J; Fan S; Zhao M; Shen J; Li X; Yang T; Lu Q; Lu Y; Bai H; Zhang H; Cai D; Wang L; Yuan Z; Jiang E; Zhou F; Song X
Cell Transplant; 2022; 31():9636897221102902. PubMed ID: 35670196
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Risk Factors of Cyclosporine-Induced Neurotoxicity in Allogeneic Stem Cell Transplant Recipients.
Danish A; Mughal SI; Zaidi U; Dildar S; Samad S; Jamal A; Sharif Z; Shamsi T
Cureus; 2021 Nov; 13(11):e19824. PubMed ID: 34963841
[TBL] [Abstract][Full Text] [Related]
9. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?
Gagelmann N; Kröger N
Haematologica; 2021 Jul; 106(7):1794-1804. PubMed ID: 33730842
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
Im HJ; Koh KN; Suh JK; Lee SW; Choi ES; Jang S; Kwon SW; Park CJ; Seo JJ
Bone Marrow Transplant; 2016 Sep; 51(9):1217-22. PubMed ID: 27159171
[TBL] [Abstract][Full Text] [Related]
12. Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
Lawitschka A; Faraci M; Yaniv I; Veys P; Bader P; Wachowiak J; Socie G; Aljurf MD; Arat M; Boelens JJ; Duarte R; Tichelli A; Peters C
Bone Marrow Transplant; 2015 Apr; 50(4):592-7. PubMed ID: 25621804
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review.
Zeng W; Huang L; Meng F; Liu Z; Zhou J; Sun H
Int J Clin Exp Med; 2014; 7(11):4357-68. PubMed ID: 25550955
[TBL] [Abstract][Full Text] [Related]
14. Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.
Im HJ; Koh KN; Suh JK; Lee SW; Choi ES; Jang S; Kwon SW; Park CJ; Seo JJ
Bone Marrow Transplant; 2015 Feb; 50(2):225-31. PubMed ID: 25310303
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Giralt S; Ballen K; Rizzo D; Bacigalupo A; Horowitz M; Pasquini M; Sandmaier B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):367-9. PubMed ID: 19203728
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease.
Hogan WJ; Storb R
Immunol Res; 2003; 28(1):1-11. PubMed ID: 12947220
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT).
Bacigalupo A
Bone Marrow Transplant; 2000 Apr; 25(8):803-5. PubMed ID: 10808199
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
